Plasma concentration and CNS effects of Ca antagonists darodipine and nimodipine after single-dose oral administration to healthy volunteers

Neuropsychobiology

Volumn 40, Issue 3, 1999, Pages 158-170

  Sannita, Walter G ^a,b,c,d   Garbarino, S ^a   Gesino, D ^a   Massimilla, S ^a   Ogliastro, C ^a  

^a DISMR   (Italy)

^b CNR   (Italy)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Acute oral administration; Ca antagonists; Darodipine; Drug plasma concentration; Healthy volunteers; Nimodipine; Quantitative EEG

Indexed keywords

CALCIUM ANTAGONIST; DARODIPINE; NIMODIPINE;

ADULT; ARTICLE; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL THRESHOLD; DRUG BLOOD LEVEL; ELECTROENCEPHALOGRAM; HEART RATE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL;

ADULT; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CENTRAL NERVOUS SYSTEM; ELECTROENCEPHALOGRAPHY; HEART RATE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NIFEDIPINE; NIMODIPINE;

EID: 0032884264     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026614     Document Type: Article

References (58)

1. Nayler WG, Poole-Wilson PA, Williams A: Hypoxia and calcium. J Mol Cell Cardiol 1979; 11:683-706.
2. Cheung JY, Bonventre JV, Malis CD, Leaf A: Calcium and ischemic injury. N Engl J Med 1986;314:1670-1676.
3. Cartheuser CF: Slow channel inhibitor effects on brain function: Tolerance to severe hypoxia in the rat. Br J Pharmacol 1988;95:903-913.
4. Stone PH, Antman EM, Muller JE, Braunwald E: Calcium channel blocking agents in the treatment of cardiovascular disorders. II. Haemodynamic effects and clinical applications. Ann Intern Med 1980;93:886-904.
5. Wiernsperger N, Gygax P, Hofmann A: Calcium antagonist PY 108-068: Demonstration of its efficacy in various types of experimental brain ischemia. Stroke 1984;15:679-685.
6. Oczkowski WJ, Hachinski VC, Bogousslavsky J, Barnett HJM, Carruthers SG: A double-blind, randomized trial of PY 108-068 in acute ischemic cerebral infarction. Stroke 1989;20: 604-608.
7. Nishijo H, Kuze S, Ono T, Tabuchi E, Endoi S, Kogure K: Calcium entry blocker ameliorates ischemic neuronal damage in monkey hippocampus. Brain Res Bull 1992;29:519-524.
8. Rasmussen H, Barren PQ: Calcium messenger system: An integrated view. Physiol Rev 1984; 64:938-984.
9. Rasmussen H: The calcium messenger system. Part 1. N Engl J Med 1986;314:1094-1101.
10. Rasmussen H. The calcium messenger system. Part 2. N Engl J Med 1986;314:1164-1170.
11. Kennedy MB: Regulation of neuronal function by calcium. Trends Neurosci 1989;12:417-420.
12. Matty A: The physiological role of calcium-dependent channels. Trends Neurosci 1989;12: 420-424.
13. Kostyuk PG, Verkhratsky AN: Calcium Signaling in the Nervous System. London, Wiley, 1995.
14. Morocutti C, Pierelli F, Sanarelli L, Stefano E, Peppe A, Mattioli G: Antiepileptic effects of a calcium antagonist (nimodipine) on cefazolin-induced epileptogenic foci in rabbits. Epilepsia 1986;27:498-503.
15. Del Pozo E, Caro G, Baeyens JM: Analgesic effects of several calcium channel blockers in mice. Eur J Pharmacol 1987;137:155-160.
16. Raeburn D, Gonzales RA: CNS disorders and calcium antagonists. Trends Pharmacol Sci 1988;9:117-118.
17. De Sarro GB, Meldrum BS, Nistico G: Anti-convulsant effects of several calcium entry blockers in DBA/2 mice. Br J Pharmacol 1988; 93:247-256.
18. Ashton D, Willelms R, Marrannes R, Janssen PA: Extracellular ions during veratridine-induced neurotoxicity in hippocampal slices: Neuroprotective effects of flunarizine and tetradotoxin. Brain Res 1990;528:212-222.
19. Moyer JR Jr, Thompson LT, Black JP, Disterhoft JF: Nimodipine increases excitability of rabbit CAl pyramidal neurons in an age-and concentration-dependent manner. J Neurophysiol 1992;68:2100-2109.
20. Pohl M, Straub, H, Speckmann EJ: Low magnesium-induced epileptiform discharges in guinea pig hippocampal slices: Depression by the organic calcium antagonist verapamil. Brain Res 1992;577:29-35.
21. Mack CM, Gilbert ME: An examination of the anticonvulsant properties of voltage-sensitive calcium channel inhibitors in amygdala kindled seizures. Psychopharmacology 1992;106: 365-369.
22. Amenta F, Mancini M, Naves FJ, Vega JA, Zaccheo D: Effect of treatment with the dihydropyridine-type calcium antagonist darodipine (PY 108-068) on the expression of calbindin D-28K immunoreactivity of the cerebral cortex of aged rats. Mech Ageing Dev 1995;77: 149-157.
23. Tsikalova R, Nikolov R, Nikolova M: Rheoen-cephalographic and electroencephalographic studies of flunarizine. Methods Find Exp Clin Pharmacol 1990;12:527-530.
24. Popoli P, Benedetti M, Scotti De Carolis A: Influence of nimodipine and diltiazem, alone and in combination, on phencyclidine-induced effects in rats: An EEG and behavioural study. Eur J Pharmacol 1990;191:141-148.
25. McDevitt DG, Currie D, Nicholson AN, Wright NA, Zetlein MB: Central effects of the calcium antagonist, nifedipine. Br J Clin Pharmacol 1991;32:541-549.
26. Sannita WG, Busico S, Di Bon G, Ferrari A, Riela S: Pharmacokinetics and electroencephalographic effects of darodipine 50-200 mg modified release (MR) acute administration: Dose-finding study in healthy volunteers. Int J Clin Pharmacol Res 1993;13:281-291.
27. Blaxter TJ, Carlen PL, Niesen C: Pharmacological and anatomical separation of calcium currents in rat dentate granule neurons in vitro. J Physiol 1989;412:93-112.
28. Hossmann KA: Treatment of experimental cerebral ischemia (review). J Cereb Blood Flow Metab 1982;2:275-297.
29. 31P NMR spectroscopy. Magn Reson Med 1987;4:1-8.
30. Urien S, Pinquier J-L, Paquette B, et al: Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the rat blood-brain barrier. Drug binding to lipoproteins does not limit the transfer of drug. J Pharmacol Exp Ther 1987;242:349-353.
31. 3H]PY 108-068. J Neural Transm 1984;60:169-197.
32. Hof RP: PY 108-068: A calcium antagonist with an unusual pattern of cardiovascular activity. Gen Pharmacol 1985;18:1-6.
33. Herbette HG, Mason PE, Sweeney KR, Trumbore MW, Mason RP: Favorable amphiphilicity of nimodipine facilitates its interactions with brain membranes. Neuropharmacology 1994; 33:241-249.
34. Dumermuth G, Ferber G, Herrmann WM, Hinrichs K, Künkel H: Recommendation for standardization of data acquisition and signal analysis in pharmaco-EEG. Neuropsychobiology 1987;17:213-218.
35. Sannita WG, Crimi E, Riela S, Rosadini G, Brusasco V: Cutaneous antihistaminic effect of cetirizine and dose-related electroencephalographic concomitants of sedation in healthy volunteers. Eur J Pharmacol 1996;300:31-41.
36. Shah VP, Midha KK, Dighe S, et al: Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 1991;16:249-255.
37. Fink M, Irwin P, Sibony P: EEG classification of a novel anorexigenic: PR-F-36-CL (comparison with placebo, dextroamphetamine, and fenfluramine); in Sudilowsky A, Gershon S, Beer B (eds): Predictability in Psychopharmacology: Preclinical and Clinical Correlations. New York, Raven Press, 1975, pp 89-103.
38. Sannita WG, Balestra V, DiBon G, Hassan KM, Rosadini G: Placebo effects in standard human neuropharmacological studies: Effects of physiological variations of blood glucose and ammonia concentration on the electrophysiology of the visual system. Neuropsychobiology 1992;25:49-60.
39. Silverstone PH, Done C, Sharp T: Clonidine but not nifedipine prevents the release of noradrenaline during naloxone-precipitated opiate withdrawal: An in vivo microdialysis study in the rat. Psychopharmacology 1992;109:235-238.
40. Yamada S, Matsuoka Y, Kato Y, Kimura R, Inagaki O: A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats. J Pharmacol Exp Ther 1992;262:589-594.
41. Gotfraind T: Calcium antagonists and vasodilatation. Pharmacol Ther 1994;64:37-75.
42. 2+ channels and their possible counterparts in mammalian CNS neurons. Neuropharmacology 1993;32:1075-1088.
43. 2+ uptake processes in rat brain. Biochem Pharmacol 1987;36: 4163-4166.
44. Katz B: The Release of Neurotransmitter Substances. Oxford, Clarendon Press, 1969.
45. Blatz AL, Magleby KL: Calcium-activated potassium channels. Trends Neurosci 1987;10: 463-467.
46. Blitzer RD, Gil O, Omsri G, Landau EM: Nifedipine blocks calcium-dependent cholinergic depolarization in the guinea pig hippocampus. Brain Res 1991;542:293-299.
47. Dickie BG, Davies JA: Calcium channel blocking agents and potassium-stimulated release of glutamate from cerebellar slices. Eur J Pharmacol 1992;229:97-99.
48. Miller JW, Ferrendelli JA: Characterization of GABAergic seizure regulation in the midline thalamus. Neuropharmacology 1990;29:649-655.
49. B receptors in excitation and inhibition of thala-mocortical cells. Trends Neurosci 1991;14:16-21.
50. 2+ currents and synaptic transmission in hippocampal neurons. J Physiol 1991;444:669-686.
51. Cousin MA, Nicholls DG, Pocock JM: Flunarizine inhibits both calcium-dependent and -independent release of glutamate from synaptosomes and cultured neurons. Brain Res 1993; 606:227-236.
52. Creutzfeldt OD, Arnold PM, Becker D, et al: EEG changes during spontaneous and controlled menstrual cycles and their correlation with psychological performance. Electroencephalogr Clin Neurophysiol 1976;40:113-131.
53. Itil TM, Laudhan G, Herrmann WM (eds): Psychotropic Action of Hormones. New York, Spectrum, 1976.
54. Hoffmeister F, Kazda S, Krause HP: Influence of nimodipine (Bay e 9736) on the post ischemic changes of brain function. Acta Neurol Scand 1979;60:358-367.
55. Marchal G, Rioux P, Petit-Taboué MC, et al: Regional cerebral oxygen consumption, blood flow and blood volume in healthy human aging. Arch Neurol 1992;49:1013-1020.
56. Nagata K, Takawa K, Hiroi S. Shishido F, Uemura K: Electroencephalographic correlates of blood flow and oxygen metabolism provided by positron emission tomography in patients with cerebral infarction. Electroencephalogr Clin Neurophysiol 1989;72:16-30.
57. Haws CW, Gourley JK, Heistad DD: Effects of nimodipine on cerebral blood flow. J Pharmacol Exp Ther 1983;225:24-28.
58. Johnson PC: Review of previous studies and current theories of autoregulation. Circ Res 1964;14-15(suppl 1):2-9.